You are here: Industry Insights > Epilepsy

News List

Manslaughter charges on Sanofi over epilepsy drug Depakine expresspharma
August 05, 2020
Sanofi Aventis France has been placed under formal investigation on charges of manslaughter over Depakine, an epilepsy drug that caused birth malfunctions and slow neurological development when taken during pregnancy.
Cobra Biologics Delivers Plasmids for CombiGene's Epilepsy Candidate contractpharma
July 14, 2020
Completes delivery of all plasmids required to progress to the next phase of the project.
NRI professor discovers new therapy for epilepsy brain disease expresspharma
June 29, 2020
This invention has clinical implications that could lead to the eventual treatment of uncontrolled seizures and epilepsy brain disease.
UCB Acquires Engage Therapeutics for $125M contractpharma
June 08, 2020
Gains Staccato Alprazolam in Phase II development as a single-use epileptic seizure rescue therapy.
Cobra Biologics Completes Key CombiGene Milestone contractpharma
April 06, 2020
Successfully produced and delivered the first DNA plasmid required to produce CombiGene’s gene therapy drug candidate.
EMA accepts Arvelle’s cenobamate MAA pharmatimes
March 30, 2020
Arvelle Therapeutics’ Marketing Authorisation Application (MAA) for cenobamate has been accepted by the European Medicines Agency (EMA).
Mercaptor Announces Epilepsy Preclinical Program americanpharmaceuticalreview
January 13, 2020
Mercaptor Discoveries announced the advancement of its preclinical program in epilepsy. The program culminates in human trials, beginning in early 2022. Their primary candidate has demonstrated reproducible POC and efficacy in animal seizure models.
Antiepileptic Drug Exposure Low in Breastfeeding Infants drugs
January 02, 2020
Among infants breastfed by mothers who are receiving drug therapy for epilepsy, antiepileptic drug (AED) concentrations in infant blood samples are substantially lower than those in ...
SK Life Science Announces IND Application Acceptance for Anti-Epileptic Drug Candidate americanpharmaceuticalreview
December 30, 2019
SK Life Science announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for SKL24741, for the treatment of epilepsy.
OWP Announces Second IND Approval for Lamotrigine Liquid Oral Suspension Formulation americanpharmaceuticalreview
December 30, 2019
OWP Pharmaceuticals has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA), and has submitted for U.S. patent protection ...

Previous page 1 2 3 4 5 6 Next page